Skip to content

The Effect of Different Doses of Remifentanil on Kidney Function During Robot Assisted Prostatectomy - A Retrospective Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02041559
Enrollment
1500
Registered
2014-01-22
Start date
2014-01-31
Completion date
2014-12-31
Last updated
2014-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Robot assisted prostatectomy reduces the patients' postoperative pain and leads to rapid rehabilitation. But pneumoperitoneum affects the kidney. The increase of stress hormone reduces the glomerular filtration and the vaso-contraction of renal vessels leads the renal ischemia. Remifentanil is analgesics coupled with μ opioid receptor. In high dose of remifentanil, it is associated with κ and δ receptors, which leads to renal protection effect in animal study. Also, remifentanil infusion during anesthesia showed a diuretic effect. The purpose of this study is to investigate the remifentanil effect on renal function during robot assisted prostatectomy.

Interventions

None listed

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* ages \> 19 years and \< 85 years * the patients undergoing a general anesthesia for robot assisted prostatectomy

Exclusion criteria

* incomplete record * history of opioid or steroid using * solitary kidney * history of kidney transplantation

Design outcomes

Primary

MeasureTime frameDescription
acute kidney injury incidence based on Acute Kidney Injury Network criteria24 hours after end of surgeryAcute kidney injury incidence based on Acute Kidney Injury Network criteria was defined as increase in serum creatinine from baseline of ≥ 0.3 mg/dl within a 48-hour period. Acute kidney injury is evaluated at POD 1.

Countries

South Korea

Contacts

Primary ContactJi Eun Kim, MD
beye98@yuhs.ac82-2-2019-6808

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026